Rheumatoid Arthritis Treatment, Product Administration, Training and Patient Assistance/Compassionate Use Program Awareness for the Specialty
|
|
- Esther Gladys Cook
- 6 years ago
- Views:
Transcription
1 Rheumatoid Arthritis Treatment, Product Administration, Training and Patient Assistance/Compassionate Use Program Awareness for the Specialty Pharmacist and the Collaborative Healthcare Team
2 Disclaimer The information within this CME/CE activity is for continuing education purposes only, and is not intended to substitute for the medical judgment of the healthcare provider. Recommendations for use of any particular therapeutic agents or methods are based upon the best available scientific evidence and clinical guidelines. Reference in this activity to any specific commercial products, process, service, manufacturer, or company does not constitute its endorsement or recommendation. Developer discloses that he is a speaker, consultant, and provides research support for the National Association of Specialty Pharmacy. He does not intend to discuss non-fda approved drugs or investigational use of any product/device.
3 Faculty Biography University of Florida 2008 Pharmacist in Charge Publix Super Markets National Association of Specialty Pharmacy Specialty Pharmacy Clinical Consultant Michael J Crocco, PharmD, RPh, CSP Specialty Pharmacy Clinical Services National Association of Specialty Pharmacy Specialty Pharmacy Education Center Reviewer/author of CE s Specialty Pharmacy Certification Board Subject matter expert in developing Certified Specialty Pharmacy Credential Certified Specialty Pharmacist
4 Objectives Recognize the various inflammatory autoimmune disorders and their distinguishing features. Identify current treatment options for RA and review their appropriate administration Identify the three biggest barriers to adherence & persistence and how Specialty Pharmacists and the collaborative healthcare team can anticipate & overcome those barriers Identify RA patient assistance programs from RA manufacturers and 3 rd parties Describe the specialty pharmacist and the collaborative healthcare team s role in RA condition management resulting in cost-effective care
5 Other Autoimmune Diseases (Brief Overview)
6 Crohn s Disease Inflammatory Bowel Disease Lining of digestive tract (mouth to anus) Signs/Symptoms Abdominal pain Severe diarrhea Blood in stool Ulcers Reduced appetite Weight loss e.svg
7 Ulcerative Colitis Inflammatory bowel disease Lining of large intestine Types of UC: Proctitis Proctosigmoiditis Left-sided Colitis Pancolitis Fulminant Colitis pg
8 Psoriatic Arthritis Enthesitis Characteristic feature Signs/Symptoms Similar to RA, plus.. Swollen fingers and toes Foot pain Lower back pain
9 Juvenile Idiopathic Arthritis Children 6 months 16 years old Types of JIA Pauciarticular Polyarticular Systemic
10 Juvenile Idiopathic Arthritis Symptoms Pain Swelling Stiffness Swollen lymph nodes Rash Fever
11 Ankylosing Spondylitis Spine Vertebrae fuse Signs/Symptoms Lower back pain Hip pain
12 Treatment Options Rheumatoid Arthritis
13 DMARDs Methotrexate (Trexall, Rheumatrex) Leflunomide (Arava) Hydroxychloroquine (Plaquenil) Sulfasalazine (Azulfidine)
14 Methotrexate Dosing Once weekly Oral or injection (IM or SQ) Titrate up as necessary Hydration Monitoring LFT s CBC w/diff Platelets BUN/Cr
15 htm Methotrexate SQ Injection 25 Gauge 1/2-5/8 inch
16 Methotrexate IM Injection 25 Gauge inch htm
17 Leflunomide Dosing Loading dose of 100mg x 3 days 20mg daily thereafter With food Monitoring BP Platelets WBC s Hgb/Hct LFT s
18 Leflunomide Drug elimination procedure Cholestyramine 8g TID x 11 days Plasma levels <0.02mg/dL 2 tests, 14 days apart If no elimination procedure Up to 2 years to reach <0.02mg/dL
19 Hydroxychloroquine Weight based dosing 6.5mg/kg /day Typically mg daily Monitoring Eye exams Yearly Keep away from children Small doses fatal
20 Sulfasalazine Dosing mg Q12H Up to 4000mg daily Monitoring CBC w/diff LFTs BUN/Cr Caution Sulfonamide allergy Salicylate allergy
21 TNFa Inhibitors Humira (Adalimumab) Enbrel (Etanercept) Cimzia (Certolizumab pegol) Simponi (Golimumab) Remicade (Infliximab)
22 Humira Dosing 40mg SQ q2wk 40mg SQ qwk if not on MTX Refrigerate Monitor Hep B antigen PPD s/sx TB and HBV Cost $2400-$2700 (2 pens/syringes)
23 Humira Administering Pen Clear/colorless liquid No particles Front of thighs/lower abdomen Clean area Gently squeeze skin and hold firmly Hold pen at 90 degree angle Push plum colored button until clicks Hold for 10 seconds Yellow Indicator = Completed Do not rub area 2IpGLsVangU/UEktd63ThII/AAAAAAAAAJw/wmt8vVOYiC8/s1600/humira1.jpg
24 Humira Administering Prefilled Syringe Clear/colorless liquid No particles Front of thighs/lower abdomen Clean area Gently squeeze skin and hold firmly Insert at 45 degree angle and let go of skin After injecting, remove at same angle Do not rub area 8QaFwE1vRfE/T819tbn5jQI/AAAAAAAAACk/gAjBd3WTGPo/s1600/humira.jpg
25 Humira Patient Assistance Programs myhumira Humira Protection Plan 24/7 on-call nurse support HUMIRA Injection training kit Sharps container Medication reminders On-the-go kit Abbvie Patient Assistance Foundation
26 Enbrel Dosing 50mg SQ qwk OR 25mg SQ 2x/wk 72-96h apart Storage Refrigerate Room temperature 14 days Monitor Hep B antigen PPD s/sx TB and HBV Dermatologic exam* Cost $2200-$3000
27 Enbrel Administering SureClick AutoInjector Clear/colorless liquid Front of thighs preferred Abdomen/outer are of upper arms Clean area Stretch skin to make it firm and taut Hold pen at 90 degree angle Press pen firmly to unlock safety guard Press and release purple button Hold firmly for 15 seconds Purple Indicator = Completed Do not rub area pg
28 Enbrel Administering Enbrel PFS Clear/colorless liquid Front of thighs/lower abdomen/outer upper arms Clean area Gently squeeze skin and hold firmly Inject at 45 degree angle Do not rub area
29 Enbrel PAP Enbrel Support Card Education Injection training Medication refill reminders Live nurse support ENBREL Starter kit Sharps mail-back program Travel pack
30 Enbrel Support Card If commercial insurance: $0 for 6 months, $10 afterwards If Government insurance: Connect with independent foundations Low-income subsidy assistance If Uninsured: ENcourage Foundation
31 Cimzia Dosing 400mg SQ on week 0, 2, 4, then 200mg SQ q2wk OR 400mg SQ q4wk Refrigerate Monitor Hep B antigen PPD s/sx TB and HBV Dermatologic exam* Cost ~$2500
32 Cimzia Administration Room temperature 30 minutes Clear/colorless liquid Front of thighs/lower abdomen Clean area Gently squeeze skin and hold firmly Inject at 45 degree angle Do not rub area
33 Cimzia PAP Cimplicity Treatment and patient support Home Health Nurse CIMZIA Education Injection training Insurance coverage verification Cimzia Co-pay Savings Card Program Up to 12 months at no cost Additional financial assistance
34 Simponi Dosing 50mg SQ monthly with MTX Refrigerate Monitor Hep B antigen PPD s/sx TB and HBV Dermatologic exam* Cost ~$8300 (5 syringes)
35 Simponi SmartJect Autoinjector Administration Room temperature 30 minutes Clear/slightly yellow Front of thighs/lower abdomen/outer area of upper arms Clean area Inject at 90 degree angle Press firmly against skin to unlock safety sleeve Press button until clicks hold until clicks again Do not rub area Shot.jpg
36 Simponi Prefilled Syringe Administration Room temperature 30 minutes Clear/slightly yellow Front of thighs/lower abdomen/back of upper arms Clean area Gently squeeze skin and hold firmly Inject at 45 degree angle Hold plunger until removed from skin then release Do not rub area PG
37 SimponiOne Support Injection Support Nurse Support MY SIMPONI RN Live Link (on-line discussion) 7 days/wk, 8am-11pm SmartJect Autoinjector Reusable Trainer Included in Welcome Pack Demonstration Videos
38 SimponiOne Support Treatment Support Simponi Welcome Pack SimponiOne Safe Returns Once a year return service Holds 12 SmartJect autoinjectors Holds more syringes Travel Pack Travel Advisory Card
39 SimponiOne Support Medication Cost Support Commercial/Private Insurance $5/month up to $8000 benefit/yr Government Insurance independent foundation No insurance Johnson & Johnson Patient Assistance Foundation Other
40 Remicade Dosing 3mg/kg IV on wk 0, 2, 6 THEN 3mg/kg IV q8wk Use with MTX Max dose 10mg/kg OR 3mg/kg q4wk Refrigerate Monitor Hep B antigen PPD s/sx TB and HBV Dermatologic exam* Cost $ for one vial (100mg)
41 Remicade Administration Colorless/light yellow By medical professional Infusion Center At least 2 hours
42 Remicade PAP AccessOne Care Coordinator Access-1 M-F, 8am-8pm EST Infusion site locations Newsletters Education materials Appointment reminders Emergency outreach services
43 Remicade PAP RemiStart Patient Rebate Program Co-pay assistance Up to 12 months, 8 infusions, or $8000 RemiStart Extended Access Program Must meet eligibility requirements
44 Other Biologics Kineret (Anakinra) Orencia (Abatacept) Rituxan (Rituximab) Actemra (Tocilizumab)
45 Kineret Dosing 100mg SQ q24h Refrigerate Monitor Cr ANC Pregnancy Category B Cost ~$3000/28 syringes
46 Kineret Prefilled Syringe Administration Sit at room temperature minutes Clear/colorless Sites Outer area of upper arms Upper outer areas of buttocks Abdomen Front of the middle thighs Gently pinch fold of skin Inject at 45 or 90 degree angle gif
47 Kineret PAP KineretKare Program Copay assistance Up to $300/month OR $3600/year Delivery of medication Access to KineretKare specialist M-F, 8am-6pm EST
48 Orencia Weight based dosing <60kg 500mg IV on wk 0, 2, 4, then q4wk OR 500mg IV x1, then 125mg SQ w/in 24hr, then 125mg SQ qwk kg same as above but 750mg IV doses >100kg same as above but 1000mg IV doses Refrigerate Monitor Cost Hepatitis panel PPD at baseline $2100/vial (250mg) $2500/4 syringes (125mg)
49 Orencia Administration IV Medical professional Reconstitute with 10ml sterile water for injection Must use silicone free syringe provided 30 minute infusion
50 Orencia Administration SQ Clear/colorless/pale yellow Room temperature minutes Sites Front of thigh Upper outer arms Abdomen Gently pinch skin and hold firmly Inject at 45 degree angle Ulnq7gEQ1NM/UqNeD7LnvSI/AAAAAAAATEo/vQpbAc01osY/s1600/orencia.jpg
51 Orencia PAP Orencia On Call Personal care counselor Available 24/ ORENCIA Copay assistance Welcome pack Sharps Disposal Service Drug Replacement If damaged Insurance questions
52 Orencia PAP Orencia Copay Assistance Program Covers cost of drug only Infusion patients $5 out of pocket per infusion $8000/year max benefit NOTE: state or federally funded insurance excluded
53 Rituxan Dosing 1000mg IV on days 1 and 15 THEN 1000mg IV q24 weeks Q16 weeks In combination with MTX Refrigerate Cost ~$15,600 (one 10ml vial = 10mg/ml)
54 Rituxan Monitoring HBsAg Anti-HBc at baseline CBC Platelets ECG s/sx of hepatitis or HBV reactivation
55 Rituxan Administration IV infusion Medical professional Pre-medicate APAP and antihistamine Methylprednisolone 100mg IV (RA patients only)
56 Rituxan Infusion Rates Initial Infusion = 50mg/hr Increase at 50mg/hr increments q30 minutes Max 400mg/hr Subsequent infusions = 100mg/hr Increase at 100mg/hr at 30 minute intervals Max 400mg/hr
57 Rituxan PAP Join Rituxan and You Genentech Rheumatology Access Solutions Genentech Access to Care Foundation Genentech Rheumatology Co-pay Card Program $10,000 over 12 months $5 per co-pay May reuse if still eligible after 12 months
58 Actemra IV Dosing 4mg/kg IV over 1 hour q4wks May increase to 8mg/kg IV q4wks Do not exceed 800mg per infusion SQ Dosing 162mg SQ qwk If pt <100kg, start at 162mg SQ q2wks Refrigerate Cost $340 (4ml vial) $850 (10ml vial) $1725 (20ml vial)
59 Actemra Monitoring PPD at baseline s/x of TB CBC w/differential (ANC s) Platelets LFT s Lipid profile
60 Actemra Administration IV Infusion Clear/colorless/pale yellow Medical professional Room temperature Infuse over 60 minutes Use separate IV line pg
61 Actemra Administration SQ Room temperature 30 minutes Sites Front of thigh Outer area of upper arm Abdomen Gently pinch skin Inject at 45 or 90 degree angle Release pinched skin and inject
62 Actemra PAP Actemra Access Sampling Program SQ patients ACT Fast Program 6 months free Support for Medicare Part D patients Refer to LIS Program Genentech Access to Care Foundation Extension
63 Actemra Access Actemra and You Symptom Tracker Calendar Doctor Discussion Guide Nurse Help Line ACTEMRA 6am-12am EST SC Injection tools Travel Pack Sharps Container Injection Reminder Service Treatment Tracker
64 Actemra Access Genentech Rheumatology Co-pay Card Program $10,000 per 12 months $5 co-pay Genentech Rheumatology Access Solutions
65 JAK inhibitor Xeljanz (Tofacitinib)
66 Xeljanz Dosing 5mg PO BID With or w/o food Room temperature Monitoring CBC w/diff Lipid panel LFT s Cost ~$2,000 (60 tablets)
67 XelSource Private Insurance Free Trial Offer Personal Support M-F, 8am-8pm EST Xeljanz Copay Savings Card $0 copay $8,000 benefit per calendar year Uninsured XelSource Patient Assistance Program
68 Xeljanz Government Insurance Personal Support Financial Assistance State Pharmaceutical Companies Low-income subsidies Charitable foundations Hardship support Xeljanz + You Welcome Kit Refill reminders Tips, Tools, and Resources
69 Other Patient Assistance Programs NeedyMeds Diplomat s Co-pay Assistance Navigator HealthWell Foundation Patient Access Network Foundation Bristol-Myers Squibb Patient Assistance Foundation Orencia Pfizer Pfriends Xeljanz
70 Other Patient Assistance Programs Partnership for Prescription Assistance Humira MedLink Prescription Assistance Enbrel Janssen Prescription Assistance Simponi, Remicade Johnson & Johnson Prescription Assistance Foundation Remicade
71 Barriers to Adherence Cost Direct Indirect Administration Complicated/intimidating Transportation/Time Infusions Side effects Cancer Infertility Pain
72 Overcoming Barriers Treatment management Counsel/Educate Side effects Self injections Insurance No more pre-existing condition Use assistance programs Home health nurse Specialty Pharmacist
73 Conclusion Multiple treatment options Biologics are expensive All have assistance programs Make patients aware Need to educate/counsel all patients
74 References Mayoclinic. Crohn s Disease. Accessed on November 19, Crohn s and Colitis Foundation of America. What is Crohn s Disease? Accessed on November 19, Mayoclinic. Ulcerative Colitis. Accessed on November 19, Crohn s and Colitis Foundation of America. What is Ulcerative Colitis. Accessed on November 19, American College of Rheumatology. Psoriatic Arthritis. Psoriatic_Arthritis/. Accessed on November 21, Mayoclinic. Psoriatic Arthritis. Accessed on November 21, 2013.
75 References Mayoclinic. Juvenile Rheumatoid Arthritis. Accessed on November 21, National Institute of Arthritis and Musculoskeletal and Skin Diseases. What is Juvenile Arthritis? Accessed on November 21, WebMD. Understanding Juvenile Rheumatoid Arthritis. Accessed on November 21, Mayoclinic. Ankylosing Spondylitis. Accessed on November 22, American College of Rheumatology. Methotrexate. xate_(rheumatrex,_trexall)/. Accessed on November 22, 2013.
76 References Brooks PJ, Spruill WJ, Parish RC, Birchmore DA. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Department of Pharmacy Practice, University of Georgia College of Pharmacy, Athens. Arthritis Rheum Jan;33(1):91-4. Mayoclinic. Leflunomide. Accessed on November 24, Sanofi-Aventis. Arava Package Insert. Accessed on November 24, Mayoclinic. Hydroxychloroquine. Accessed on December 5, Mayoclinic. Sulfasalazine. Accessed on December 5, 2013.
77 References Patient Assistance Programs. Accessed January 20, 2014 February 27, Humira Product Information and Patient Assistance Programs. Accessed on January 15, Enbrel Product Information and Patient Assistance Programs. Accessed on January 15, Cimzia Product Information and Patient Assistance Programs. Accessed on January 16, Simponi Product Information and Patient Assistance Programs. Accessed on January 16, Remicade Product Information and Patient Assistance Programs. Accessed on January 18, Kineret Product Information and Patient Assistance Programs. Accessed on January 24, 2014.
78 References Orencia Product Information and Patient Assistance Programs. Accessed on January 31, Rituxan Product Information and Patient Assistance Programs. Accessed on February 10, Actemra Product Information and Patient Assistance Programs. Accessed on February 12, Xeljanz Product Information and Patient Assistance Programs. Accessed on February 15, Micromedex Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Epocrates Epocrates Mobile Application. Retrieved from
79 Q & A
80 This program has been brought to you by The National Association of Specialty Pharmacy and its education provider The Specialty Pharma Education Center. Claim Credit Instructions: Visit & type session code: (session codes are also located in your program guide on the activity sheet page) *All users must complete the pre AND post test to receive statement of credit. Credit must be claimed within 30 days of this program.
RHEUMATOID ARTHRITIS DRUGS
Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
Program Number 2017 P 3041-8 Program Step Therapy Medications UnitedHealthcare Pharmacy Clinical Pharmacy Programs *Orencia (abatacept) *This step criteria refers to the subcutaneous formulation of abatacept
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationBiologic Immunomodulators Prior Authorization with Quantity Limit Program Summary
Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit (with a preferred option) OBJECTIVE The intent of the
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationThe ORENCIA (abatacept) JIA Observational Registry
Moderate to Severe Juvenile Idiopathic Arthritis (JIA) Injection for Intravenous Use Injection for Subcutaneous Use The ORENCIA (abatacept) JIA Observational Registry Injection for Intravenous Use Injection
More informationGet an Insurance Benefits Review for ORENCIA (abatacept)
Get an Insurance Benefits Review for ORENCIA (abatacept) If you and your doctor decide that ORENCIA is right for you, you can call 1-800-ORENCIA (1-800-673-6242) to do an Insurance Benefits Review. Our
More informationDrugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending
Policy Subject: Anti-TNF Agents Policy Number: SHS PBD16 Category: Rheumatology & Autoimmune Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More informationACTEMRA (tocilizumab)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 6 Last Review Date: December 8, 2017 Orencia Description Orencia (abatacept)
More informationCosentyx. Cosentyx (secukinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx
More information(continued) MEDICATION GUIDE Rx Only KEVZARA (KEV-za-ra) (sarilumab) injection, for subcutaneous use
MEDICATION GUIDE KEVZARA (KEV-za-ra) (sarilumab) injection, for subcutaneous use Rx Only What is the most important information I should know about KEVZARA? KEVZARA can cause serious side effects including:
More informationPATIENT INFORMATION. ORENCIA (oh-ren-see-ah) (abatacept) Lyophilized Powder for Intravenous Infusion
PATIENT INFORMATION ORENCIA (oh-ren-see-ah) (abatacept) Lyophilized Powder for Intravenous Infusion ORENCIA (oh-ren-see-ah) (abatacept) Injection, Solution for Subcutaneous Administration Read this Patient
More informationEasy as knowing how to take the next step.
To enroll and activate: Visit Simponi.JanssenCarePathSavings.com For adults with moderate to severe rheumatoid arthritis (RA) with methotrexate, active psoriatic arthritis alone or with methotrexate, or
More informationSimponi / Simponi ARIA (golimumab)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 6 Last Review Date: September 15, 2016 Simponi / Simponi
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 6 Last Review Date: March 16, 2018 Xeljanz Description Xeljanz, Xeljanz
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationMEDICATION GUIDE Rx Only KEVZARA (KEV-za-ra) (sarilumab) injection, for subcutaneous use What is the most important information I should know about
MEDICATION GUIDE KEVZARA (KEV-za-ra) (sarilumab) injection, for subcutaneous use Rx Only What is the most important information I should know about KEVZARA? KEVZARA can cause serious side effects including:
More informationOtezla. Otezla (apremilast) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background
More informationClinical Policy: Abatacept (Orencia) Reference Number: ERX.SPA.123 Effective Date:
Clinical Policy: (Orencia) Reference Number: ERX.SPA.123 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationMEDICATION GUIDE SIMPONI (SIM-po-nee) (golimumab)
MEDICATION GUIDE SIMPONI (SIM-po-nee) (golimumab) Read the Medication Guide that comes with SIMPONI before you start taking it and each time you get a refill. There may be new information. This Medication
More informationINSTRUCTIONS FOR USE ORENCIA (oh-ren-see-ah) (abatacept) Prefilled Syringe with BD UltraSafe Passive Needle Guard
INSTRUCTIONS FOR USE ORENCIA (oh-ren-see-ah) (abatacept) Prefilled Syringe with BD UltraSafe Passive Needle Guard ORENCIA Prefilled Syringe with BD UltraSafe Passive TM Needle Guard (abatacept) Injection
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi
More informationFirst Name. Specialty: Fax. First Name DOB: Duration:
Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and
More informationBACK FIGHT. It s time to. Take action today. Ask your rheumatologist about ORENCIA.
For moderate to severe Rheumatoid Arthritis (RA) It s time to FIGHT BACK Model, not actual patient. Take action today. Ask your rheumatologist about ORENCIA. What is ORENCIA? ORENCIA (abatacept) is a prescription
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More informationFml Limits. Azathioprine (Imuran) 50mg, 75mg, 100mg - $26.85 Cyclosporine, 25mg, 100mg. $ Leflunomide (Arava) 10mg Tablet - $144.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Rheumatoid Arthritis (RA) P&T DATE: 2/15/2017 CLASS: Rheumatology/Anti-inflammatory Disorders REVIEW HISTORY 2/16, 5/15,
More informationRemicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Remicade Page: 1 of 9 Last Review Date: June 22, 2017 Remicade Description Remicade (infliximab),
More informationCenter for Evidence-based Policy
P&T Committee Brief Targeted Immune Modulators: Comparative Drug Class Review Alison Little, MD Center for Evidence-based Policy Oregon Health & Science University 3455 SW US Veterans Hospital Road, SN-4N
More informationActemra. Actemra (tocilizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.12 Subject: Actemra Page: 1 of 13 Last Review Date: September 20, 2018 Actemra Description Actemra
More informationMEDICATION GUIDE HUMIRA
MEDICATION GUIDE HUMIRA (Hu-MARE-ah) (adalimumab) injection Read the Medication Guide that comes with HUMIRA before you start taking it and each time you get a refill. There may be new information. This
More informationRemicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subsection: Gastrointestinal nts Original Policy Date: May 20, 2011 Subject: Remicade Page: 1 of
More informationo Your healthcare provider should test you for TB before starting CIMZIA.
Medication Guide CIMZIA (CIM-zee-uh) (certolizumab pegol) lyophilized powder or solution for subcutaneous use Read the Medication Guide that comes with CIMZIA before you start using it, and before each
More informationClinical Policy: Ustekinumab (Stelara) Reference Number: ERX.SPA.01 Effective Date:
Clinical Policy: (Stelara) Reference Number: ERX.SPA.01 Effective Date: 04.01.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationDrug Class Review Targeted Immune Modulators
Drug Class Review Targeted Immune Modulators Final Update 5 Report June 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationADALIMUMAB Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationMedication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013
Medication Policy Manual Policy No: dru289 Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1,
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Subject: Cimzia Page: 1 of 5 Last Review Date: December 8, 2017 Cimzia Description Cimzia (certolizumab
More informationKEEP UP THE FIGHT WITH. Little Victories
FOR MODERATE TO SEVERE RHEUMATOID ARTHRITIS (RA) KEEP UP THE FIGHT WITH Little Victories Small improvements in your daily activities may be a sign that ORENCIA (abatacept) is working for you. Use this
More informationPharmacy Medical Necessity Guidelines: Orencia (abatacept)
Pharmacy Medical Necessity Guidelines: Effective: October 23, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review SQ: RXUM/ RX / Pharmacy (RX) or
More informationMEDICATION GUIDE. (tocilizumab)
MEDICATION GUIDE ACTEMRA (AC-TEM-RA) (tocilizumab) Read this Medication Guide before you start ACTEMRA and before each infusion. There may be new information. This Medication Guide does not take the place
More informationMEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib)
MEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib) Read this Medication Guide before you start taking XELJANZ and each time you get a refill. There may be new information. This Medication Guide does not
More informationFor Rheumatoid Arthritis
For Rheumatoid Arthritis APRIL 2017 NOTICE: On April 14, 2017 the FDA issued a complete response letter for baricitinib indicating that the FDA is unable to approve the application in its current form
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cimzia Page: 1 of 5 Last Review Date: March 17, 2017 Cimzia Description Cimzia (certolizumab pegol)
More informationClinical Policy: Anakinra (Kineret) Reference Number: ERX.SPA.135 Effective Date:
Clinical Policy: (Kineret) Reference Number: ERX.SPA.135 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationWHAT YOU SHOULD KNOW ABOUT RoACTEMRA
RoACTEMRA (tocilizumab) IV and SC for Rheumatoid Arthritis WHAT YOU SHOULD KNOW ABOUT RoACTEMRA This brochure provides key information to assist in the patient s understanding of the benefits and risks
More informationCarelirst.+.V Family of health care plans
Carelirst.+.V Family of health care plans CVS Caremark POLICY Document for ACTEMRA The overall objective of this policy is to support the appropriate and cost effective use of the medication, specific
More information1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
More informationDrug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases
Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy
More informationBIOLOGICS & What You Need to Know
BIOLOGICS & What You Need to Know Biologic are given to improve how your immune system works & helps to control your disease. They are highly specific genetic copies of human proteins, given as s or infusions
More informationClinical Policy: Etanercept (Enbrel), Etanercept-szzs (Erelzi) Reference Number: ERX.SPA.07 Effective Date:
Clinical Policy: Etanercept (Enbrel), Etanercept-szzs (Erelzi) Reference Number: ERX.SPA.07 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy
More informationcertolizumab pegol (Cimzia )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationWhile every patient s experience is different, here are the general findings from clinical trials:
Indications: CIMZIA (certolizumab pegol) is approved for the treatment of adults with moderate to severe active rheumatoid arthritis (RA), active psoriatic arthritis (PsA), and active ankylosing spondylitis
More informationORENCIA (oh-ren-see-ah) (abatacept)
17.7 FDA-Approved Patient Labeling PATIENT INFORMATION ORENCIA (oh-ren-see-ah) (abatacept) Read this Patient Information before you start receiving ORENCIA and each time before you are scheduled to receive
More informationMedication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014
Medication Policy Manual Policy No: dru342 Topic: Otezla, apremilast Date of Origin: May 9, 2014 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1, 2015 IMPORTANT
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior
More informationClinical Policy: Tofacitinib (Xeljanz, Xeljanz XR) Reference Number: ERX.SPA.110 Effective Date:
Clinical Policy: Tofacitinib (Xeljanz, Xeljanz XR) Reference Number: ERX.SPA.110 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important
More informationImmune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
More informationBiologics for Autoimmune Diseases
Biologics for Autoimmune Diseases Goal(s): Restrict use of biologics to OHP funded conditions and according to OHP guidelines for use. Promote use that is consistent with national clinical practice guidelines
More informationSteps TO HELP YOU TALK WITH YOUR DOCTOR ABOUT YOUR TREATMENT OPTIONS
Moderate to Severe Rheumatoid Arthritis (RA) 3 Steps TO HELP YOU TALK WITH YOUR DOCTOR ABOUT YOUR TREATMENT OPTIONS INDICATION/USAGE Adult Rheumatoid Arthritis (RA): ORENCIA (abatacept) is a prescription
More information(tofacitinib) are met.
Xeljanz (tofacitinib) Policy Number: 5.01. 560 Origination: 3/2014 Last Review: 3/2014 Next Review: 3/2015 Policy BCBSKC will provide coverage for Xeljanz (tofacitinib) when it is determined to be medically
More informationDEDICATED SUPPORT TO HELP YOU GET STARTED AND STAY ON TRACK THROUGHOUT YOUR TREATMENT
LET US HELP YOU FIND A CLEARER PATH FORWARD. DEDICATED SUPPORT TO HELP YOU GET STARTED AND STAY ON TRACK THROUGHOUT YOUR TREATMENT PERSONALIZED SUPPORT FREE MEDICATION* $0 CO-PAY* WELCOME KIT RECYCLABLE
More informationWhile every patient s experience is different, here are the general findings from clinical trials:
Indications: CIMZIA (certolizumab pegol) is approved for the treatment of adults with moderate to severe active rheumatoid arthritis (RA), active psoriatic arthritis (PsA), and active ankylosing spondylitis
More informationPharmacy Management Drug Policy
SUBJECT: Inflammatory Conditions Clinical Review Prior Authorization (CRPA) Rx and Medical Drugs POLICY NUMBER: PHARMACY-73 EFFECTIVE DATE: 01/01/2018 LAST REVIEW DATE: 06/11/2018 If the member s subscriber
More informationClinical Policy: Tocilizumab (Actemra) Reference Number: CP.PHAR.263 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Actemra) Reference Number: CP.PHAR.263 Effective Date: 07.01.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the
More informationDrug Class Review Targeted Immune Modulators
Drug Class Review Targeted Immune Modulators Final Update 3 Report March 2012 The Agency for Healthcare Research and Quality has not yet seen or approved this report The purpose of the is to summarize
More informationCIMZIA (certolizumab pegol)
CIMZIA (certolizumab pegol) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationOrencia (abatacept) DRUG.00040
Market DC Orencia (abatacept) DRUG.00040 Override(s) Prior Authorization Quantity Limit Approval Duration 1 year Medications Comments Quantity Limit Orencia (abatacept) - AGP, VA MCD only 4 vials per 28
More informationAnnouncing HUMIRA. Psoriasis Starter Package
Announcing HUMIRA (adalimumab) Psoriasis Starter Package HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy
More informationETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL 18830 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationRheumatoid Arthritis Update. Whitney White, Pharm.D., BCPS Associate Professor of Pharmacy Practice Samford University McWhorter School of Pharmacy
Rheumatoid Arthritis Update Whitney White, Pharm.D., BCPS Associate Professor of Pharmacy Practice Samford University McWhorter School of Pharmacy Disclosures I declare that neither I nor any member of
More informationDr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria
Dr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria Inter-Balkan meeting Open the frontiers and exchange of experiences, 27 th April 2013, Rhodes, Greece Patients with
More informationSpecialty Pharmacies: What they are. Why they are different.
Specialty Pharmacies: What they are. Why they are different. A changing environment of medicines and pharmacies. Filling a prescription used to be as simple as going to the corner drug store. Today, the
More informationDrug Therapy Guidelines
Simponi, Simponi Aria Applicable Medical Benefit x Effective: 2/13/18 Pharmacy- Formulary 1 x Next Review: 12/18 Pharmacy- Formulary 2 x Date of Origin: 7/2010 Pharmacy- Formulary 3/Exclusive x Review
More informationMedication Guide Enbrel (en-brel) (etanercept)
Medication Guide Enbrel (en-brel) (etanercept) Read the Medication Guide that comes with Enbrel before you start using it and each time you get a refill. There may be new information. This Medication Guide
More informationSTEP-BY-STEP DOSING AND ADMINISTRATION GUIDE
RoACTEMRA (tocilizumab) Rheumatoid Arthritis (IV and SC formulation) and Giant Cell Arteritis (SC formulation only) STEP-BY-STEP DOSING AND ADMINISTRATION GUIDE A guide to assist healthcare professionals
More informationC. Assess clinical response after the first three months of treatment.
Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit
More informationAmjevita (adalimumab-atto)
*- Florida Healthy Kids Amjevita (adalimumab-atto) Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2 #* ^ prefilled
More informationCyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65
Market DC Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65 Override(s) Prior Authorization Quantity Limit Medications Cyltezo (adalimumab-adbm) 40 mg/0.8 ml prefilled syringe #* ^ Approval Duration 1 year
More informationA Clinical Context Report
Rheumatoid Arthritis in Practice An Expert Commentary with Diane Horowitz, MD A Clinical Context Report Rheumatoid Arthritis in Practice Jointly Sponsored by: and Rheumatoid Arthritis in Practice Expert
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More information2017 Blue Cross and Blue Shield of Louisiana
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationClinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Cimzia ) is a tumor necrosis
More informationKineret (anakinra) When Policy Topic is covered Kineret (anakinra) requires prior authorization through the pharmacy services area.
Kineret (anakinra) Policy Number: 5.01.622 Last Review: 3/2018 Origination: 3/2017 Next Review: 3/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Kineret (anakinra)
More informationRemicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximababda)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subject: Infliximab Page: 1 of 13 Last Review Date: December 8, 2017 Infliximab Description Remicade
More informationRegulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.12 Subject: Entyvio Page: 1 of 7 Last Review Date: September 20, 2018 Entyvio Description Entyvio
More informationRegulatory Status FDA-approved indication: Humira and Amjevita are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.29 Subject: Humira Page: 1 of 14 Last Review Date: June 22, 2018 Humira Description Humira (adalimumab),
More informationClinical Policy: Sarilumab (Kevzara) Reference Number: CP.PHAR.346 Effective Date: Last Review Date: 11.18
Clinical Policy: (Kevzara) Reference Number: CP.PHAR.346 Effective Date: 07.18.17 Last Review Date: 11.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationRegulatory Status FDA-approved indication: Enbrel and Erelzi are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.27 Subject: Enbrel Page: 1 of 8 Last Review Date: March 16, 2018 Enbrel Description Enbrel (etanercept),
More informationSpring How will that pipeline drug impact my benefit plan?
Spring 2012 How will that pipeline drug impact my benefit plan? How will that pipeline drug impact my benefit plan? It can be difficult to predict the impact pipeline drugs will have once they reach the
More informationClinical Policy: Anakinra (Kineret) Reference Number: CP.PHAR.244 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Kineret) Reference Number: CP.PHAR.244 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More information